Research map: Organoid-based evaluation of SA55 and Pemivibart against evolving SARS-CoV-2 variants

Back to the article

Papers in this map

  1. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2 · Markus Hoffmann · 2020 · 515 citations · Cited by this paper
  2. Rapid differentiation of VLA1553 and wild-type ECSA chikungunya strains in the context of an IXCHIQ vaccination campaign · 2026 · Related
  3. Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75 · Yunlong Cao · 2022 · 191 citations · Cited by this paper
  4. Deletion of the D345L gene attenuates ASFV and induces protection against homologous and heterologous challenge by enhancing host innate immunity · 2026 · Related
  5. Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents · Yunlong Cao · 2022 · 177 citations · Cited by this paper
  6. Transmitted and pretreatment drug resistance among 69 HIV-1 CRFs in China: the first systematic analysis · 2026 · Related
  7. Antigenic and virological characteristics of SARS-CoV-2 variants BA.3.2, XFG, and NB.1.8.1 · Caiwan Guo · 2025 · 96 citations · Cited by this paper
  8. Quantifying the community transmission of Mycobacterium tuberculosis in a rapidly growing Chinese city: a nine-year population-based genomic and spatial analysis · 2026 · Related
  9. A bipotential organoid model of respiratory epithelium recapitulates high infectivity of SARS-CoV-2 Omicron variant · Man Chun Chiu · 2022 · 88 citations · Cited by this paper
  10. Differential properties of NS1 glycoproteins in West Nile and Usutu viruses · 2026 · Related
  11. Human airway and nasal organoids reveal escalating replicative fitness of SARS-CoV-2 emerging variants · Cun Li · 2023 · 75 citations · Cited by this paper
  12. Spatiotemporal dynamics of the unprecedented chikungunya outbreak in Guangdong, China · 2026 · Related
  13. Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies · Delphine Planas · 2024 · 49 citations · Cited by this paper
  14. Intranasal drop of multiplex RNA therapy for SARS-CoV-2 infections: baicalein-enhanced FEN1 nuclease cleaving as a virus buster · 2026 · Related
  15. Activity of Research-Grade Pemivibart against Recent SARS-CoV-2 JN.1 Sublineages · Qian Wang · 2024 · 35 citations · Cited by this paper
  16. Distinct effects of GES variants on ceftazidime-avibactam and imipenem-relebactam resistance in carbapenem-resistant Pseudomonas aeruginosa : a ten-year retrospective study · 2026 · Related
  17. Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY) · Cameron R. Wolfe · 2025 · 14 citations · Cited by this paper
  18. Population genomics reveals a long-term increase in azole resistance associated with the emerging cluster AZR among Candida tropicalis causing invasive infections · 2026 · Related
  19. New Guidance Helps Clinicians Use Pemivibart to Protect Immunocompromised Patients From COVID-19 · Anna Bock · 2024 · 8 citations · Cited by this paper
  20. Organoid-based neutralization assays reveal a distinctive profile of SARS-CoV-2 antibodies and recapitulate the real-world efficacy · Zhixin Wan · 2025 · 8 citations · Cited by this paper
  21. Safety and Intranasal Retention of a Broad-Spectrum Anti-SARS-CoV-2 Monoclonal Antibody SA55 Nasal Spray in Healthy Volunteers: A Phase I Clinical Trial · Chaoying Hu · 2024 · 7 citations · Cited by this paper
  22. Neutralization of recent SARS-CoV-2 variants by genetically and structurally related mAbs of the pemivibart lineage · Colin Powers · 2024 · 5 citations · Cited by this paper
  23. Clinical Pharmacology Approaches to Predict Efficacy of Monoclonal Antibodies Against Emerging SARS ‐ CoV ‐2 Variants · Qianwen Wang · 2025 · 2 citations · Cited by this paper
  24. Antibody Transcytosis and Neutralizing Activity in Respiratory Epithelial Cells · Eduardo Anaya · 2026 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)